Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.

Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.

Abstract: The present invention relates to multispecific antibodies that bind to HLA-G ant to a T cell activating antigen, their preparation, formulations and methods of using the same.

Abstract: The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.

Abstract: The invention relates to novel antibodies particularly suitable for cancer therapies. The antibodies according to the invention are bispecific or multispecific antibodies and comprise a first antigen binding site that binds to LAG3. The first antigen binding site is an autonomous VH domain.

Abstract: The present invention relates to anti-brain target agents and therapeutic uses thereof.

Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.

Abstract: Herein is reported a method for the determination of the simultaneous binding of a bispecific antibody to a first and a second antigen comprising the steps of a) incubating a cell expressing cell-membrane bound FRET-donor-tagged first antigen and FRET-acceptor-tagged second antigen with the bispecific antibody, and b) determining the simultaneous binding of the bispecific antibody by determining the energy transfer from the FRET-donor to the FRET-acceptor.

Abstract: The invention provides anti-TPBG antibodies and methods of using the same.

Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.

Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.

Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Abstract: The invention provides anti-TPBG antibodies and methods of using the same.

Abstract: A resonator (1) has at least first and second annular chambers (2, 3, 17) arranged between inlet and outlet pieces (22, 21). An inner pipe (4) extends between the inlet piece (22) and the outlet piece (21) and has wall holes (23) that connect to the annular chambers (2, 3, 17). The first annular chamber (2) has a U-shaped circumferential wall (6) coaxial to the resonator longitudinal axis (5) and transitions at both ends to engage the inner pipe (4). The second annular chamber (3) has an L-shaped circumferential wall (12) coaxial to the resonator longitudinal axis (5). An end of the L-shaped circumferential wall remote from the first annular chamber (2) transitions into a cylindrical end piece (13), and an opposite end of the L-shaped circumferential wall lies on part of the outer wall (9) of the first annular chamber (2) extending parallel to the resonator longitudinal axis (5).

Abstract: Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.

Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.

Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Abstract: The present invention relates to anti-brain target agents and therapeutic uses thereof.

Abstract: Herein is reported a method for the determination of the simultaneous binding of a bispecific antibody to a first and a second antigen comprising the steps of a) incubating a cell expressing cell-membrane bound FRET-donor-tagged first antigen and FRET-acceptor-tagged second antigen with the bispecific antibody, and b) determining the simultaneous binding of the bispecific antibody by determining the energy transfer from the FRET-donor to the FRET-acceptor.

Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.